ID: ALA101871

Max Phase: Preclinical

Molecular Formula: C25H22FN3O6

Molecular Weight: 479.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@]1([C@H]2Cc3ccc4c(c3O2)-n2cc(C(=O)O)c(=O)c3cc(F)c(N5CC[C@H](N)C5)c(c32)O4)CO1

Standard InChI:  InChI=1S/C25H22FN3O6/c1-25(10-33-25)17-6-11-2-3-16-20(22(11)35-17)29-9-14(24(31)32)21(30)13-7-15(26)19(23(34-16)18(13)29)28-5-4-12(27)8-28/h2-3,7,9,12,17H,4-6,8,10,27H2,1H3,(H,31,32)/t12-,17+,25+/m0/s1

Standard InChI Key:  CKDNHQVHGHKQIG-KHCFPHODSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 479.46

Molecular Weight (Monoisotopic): 479.1493

AlogP: 2.56

#Rotatable Bonds: 3

Polar Surface Area: 119.55

Molecular Species: ZWITTERION

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.14

CX Basic pKa: 9.63

CX LogP: -0.20

CX LogD: -0.19

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.43

Np Likeness Score: 0.59

References

1. Kim MY, Na Y, Vankayalapati H, Gleason-Guzman M, Hurley LH..  (2003)  Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.,  46  (14): [PMID:12825936] [10.1021/jm030096i]

2. Gomes AR, Varela CL, Tavares-da-Silva EJ, Roleira FMF..  (2020)  Epoxide containing molecules: A good or a bad drug design approach.,  201  [PMID:32526552] [10.1016/j.ejmech.2020.112327]

Source

Source(1):

• Scientific Literature